Anne Hickman

561 total citations
32 papers, 360 citations indexed

About

Anne Hickman is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Anne Hickman has authored 32 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Molecular Biology and 11 papers in Surgery. Recurrent topics in Anne Hickman's work include Diabetes Treatment and Management (18 papers), Metabolism, Diabetes, and Cancer (13 papers) and Pancreatic function and diabetes (5 papers). Anne Hickman is often cited by papers focused on Diabetes Treatment and Management (18 papers), Metabolism, Diabetes, and Cancer (13 papers) and Pancreatic function and diabetes (5 papers). Anne Hickman collaborates with scholars based in United States, France and United Kingdom. Anne Hickman's co-authors include Steven G. Terra, Haihong Shi, Vaishali Sahasrabudhe, Ira Gantz, Shrita M. Patel, David L. Cutler, Kyle Matschke, Yali Liang, Susan Zhou and Didier Saur and has published in prestigious journals such as Blood, Diabetologia and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Anne Hickman

31 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne Hickman United States 13 201 132 94 62 60 32 360
Andreas Port Germany 10 218 1.1× 159 1.2× 80 0.9× 62 1.0× 92 1.5× 15 435
Ryoko Motonaga Japan 11 199 1.0× 163 1.2× 100 1.1× 26 0.4× 59 1.0× 20 354
Ning Zu China 10 127 0.6× 134 1.0× 51 0.5× 63 1.0× 13 0.2× 17 442
Saloua El Messaoudi Netherlands 12 107 0.5× 177 1.3× 105 1.1× 28 0.5× 37 0.6× 39 505
Kavita Shalia India 10 81 0.4× 57 0.4× 74 0.8× 44 0.7× 31 0.5× 32 334
Kevin Yang China 11 218 1.1× 149 1.1× 61 0.6× 50 0.8× 15 0.3× 19 392
Na Yang China 10 161 0.8× 108 0.8× 79 0.8× 87 1.4× 104 1.7× 25 421
Markus Neef Germany 11 86 0.4× 89 0.7× 225 2.4× 100 1.6× 29 0.5× 15 593
Beata Marie Redublo Quinto Brazil 12 78 0.4× 84 0.6× 55 0.6× 25 0.4× 38 0.6× 33 358
Olivera Marsenić United States 10 126 0.6× 88 0.7× 119 1.3× 25 0.4× 19 0.3× 32 396

Countries citing papers authored by Anne Hickman

Since Specialization
Citations

This map shows the geographic impact of Anne Hickman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Hickman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Hickman more than expected).

Fields of papers citing papers by Anne Hickman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Hickman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Hickman. The network helps show where Anne Hickman may publish in the future.

Co-authorship network of co-authors of Anne Hickman

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Hickman. A scholar is included among the top collaborators of Anne Hickman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Hickman. Anne Hickman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elmeliegy, Mohamed, Andrea Viqueira, Erik Vandendries, et al.. (2025). Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Targeted Oncology. 20(2). 349–359. 2 indexed citations
2.
Wang, Diane, et al.. (2025). Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma. The Journal of Clinical Pharmacology. 66(1). e70130–e70130.
3.
Prince, H. Miles, Nizar J. Bahlis, Paula Rodríguez‐Otero, et al.. (2024). MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 144(Supplement 1). 4738–4738. 5 indexed citations
4.
Brown, Mark T., David R. Cornblath, Martin Koltzenburg, et al.. (2023). Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clinical Drug Investigation. 43(7). 551–563. 3 indexed citations
5.
Guermazi, Ali, Frank W. Roemer, Andrew J. Kompel, et al.. (2022). Inter-reader consistency and exclusionary findings during radiographic screening for Phase 3 trials of tanezumab in patients with osteoarthritis. PubMed. 2(3-4). 100082–100082. 3 indexed citations
6.
Shinde, Mayura, David Carrell, Aaron B. Mendelsohn, et al.. (2022). Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis. BMC Musculoskeletal Disorders. 23(1). 883–883. 7 indexed citations
7.
8.
Elmeliegy, Mohamed, Andrea Viqueira, Erik Vandendries, et al.. (2022). Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma. Blood. 140(Supplement 1). 7174–7175. 12 indexed citations
9.
Wang, Tongtong, Shrita M. Patel, Anne Hickman, et al.. (2020). SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study. Diabetes Therapy. 11(3). 711–723. 23 indexed citations
10.
Cherney, David Z.I., Hiddo J.L. Heerspink, Robert Frederich, et al.. (2020). Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 63(6). 1128–1140. 33 indexed citations
11.
Patel, Shrita M., Anne Hickman, Robert Frederich, et al.. (2020). Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy. 11(6). 1347–1367. 18 indexed citations
12.
Liu, Jie, Lisa Tarasenko, Annpey Pong, et al.. (2020). Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion. 36(8). 1277–1284. 4 indexed citations
13.
Matschke, Kyle, Yali Liang, Hua Wei, et al.. (2019). Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. Clinical Pharmacology in Drug Development. 8(7). 884–894. 4 indexed citations
14.
Liang, Yali, Haihong Shi, Anne Hickman, et al.. (2019). Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. Clinical Pharmacology in Drug Development. 9(1). 50–61. 8 indexed citations
15.
Sahasrabudhe, Vaishali, Steven G. Terra, Anne Hickman, et al.. (2018). Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. Clinical Therapeutics. 40(10). 1701–1710. 19 indexed citations
16.
Sahasrabudhe, Vaishali, Yali Liang, Kyle Matschke, et al.. (2018). Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. Clinical Therapeutics. 40(9). 1538–1547. 19 indexed citations
17.
Cutler, David L., Susan Zhou, Rajesh Krishna, et al.. (2018). Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects. Clinical Pharmacology in Drug Development. 8(3). 314–325. 22 indexed citations
18.
Sahasrabudhe, Vaishali, Kyle Matschke, Haihong Shi, et al.. (2018). Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin. Clinical Pharmacology in Drug Development. 8(5). 619–627. 23 indexed citations
19.
Li, Jin, Brian S. Bronk, John P. Dirlam, et al.. (2007). In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity. Bioorganic & Medicinal Chemistry Letters. 17(7). 1996–1999. 13 indexed citations
20.
Li, Jin, Peter Bertinato, Hengmiao Cheng, et al.. (2006). Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents. Bioorganic & Medicinal Chemistry Letters. 16(11). 3039–3042. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Port Breakdown of academic impact, for papers by Ryoko Motonaga Breakdown of academic impact, for papers by Ning Zu Breakdown of academic impact, for papers by Saloua El Messaoudi Breakdown of academic impact, for papers by Kavita Shalia Breakdown of academic impact, for papers by Kevin Yang Breakdown of academic impact, for papers by Na Yang Breakdown of academic impact, for papers by Markus Neef Breakdown of academic impact, for papers by Beata Marie Redublo Quinto Breakdown of academic impact, for papers by Olivera Marsenić
Rankless by CCL
2026